As a new compound within the class of dopaminergic stabilisers, ACR343 has by the WHO been granted the generic name INN name seridopidine.
Seridopidine has shown effect in several preclinical models representing the primary disease characteristics related to schizophrenia. Based on its pharmacological profile, the compound is expected to be able to treat certain symptoms of schizophrenia patients, which today cannot be treated efficiently and without causing loss of motor function or weight gain. NeuroSearch is working on preparing seridopidine for clinical Phase II in the treatment of schizophrenia.
Concurrently with the above preparations, NeuroSearch has decided to evaluate the potential of seridopidine also in treating selected neurologic speciality indications.
The first Phase II study is expected to be initiated in the first half of 2011.
